Kocheva S A, Martinova K, Antevska-Trajkova Z, Coneska-Jovanova B, Eftimov A, Dimovski A J
University Children's Hospital, Medical Faculty, University "St. Cyril and Methodius," Skopje, Republic of Macedonia.
Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, University "St. Cyril and Methodius," Skopje, Republic of Macedonia.
Balkan J Med Genet. 2016 Aug 2;19(1):91-94. doi: 10.1515/bjmg-2016-0012. eCollection 2016 Jul 1.
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive chromosomal instability disorder characterized by microcephaly, immunodeficiency, radiosensitivity and a very high predisposition to malignancy. The gene responsible for the disease, , is located on chromosome 8q21 and encodes a protein called nibrin. After identification of the gene, a truncating 5 bp deletion, 657-661delACAAA, was identified as the disease-causing mutation in patients with the NBS. In this report, we describe two patients with NBS and T-lymphoblastic leukemia/lymphoma in a Macedonian family. To the best of our knowledge, this is the first family with NBS reported from Macedonia. Both children presented with microcephaly, syndactyly and the development of T cell lymphoblastic lekemia/lymphoma at the age of 7 and 10 years, respectively. The molecular analysis of genes in our patients showed homozygosity for the 657del5 mutation in the gene. The parents were heterozygotes for the 657del5 mutation and they had no knowledge of a consanguineous relationship. The first child was treated with the International Berlin-Frankfurt-Münster (BFM)-Non Hodgkin lymphoma (NHL) protocol and achieved a complete remission that lasted for 21 months. Subsequently, he developed a medullar relapse with hyperleukocytosis and died due to lethal central nervous system (CNS) complications. The second child was treated according to the International Collaborative Treatment Protocol for Children and Adolescents with Acute Lymphoblastic Leukemia 2009 (AIOP-BFM ALL 2009) protocol. Unfortunately, remission was not achieved.
奈梅亨断裂综合征(NBS)是一种罕见的常染色体隐性染色体不稳定疾病,其特征为小头畸形、免疫缺陷、放射敏感性以及极高的恶性肿瘤易感性。导致该疾病的基因位于8号染色体q21上,编码一种名为尼布林的蛋白质。在该基因被鉴定出来后,一个5bp的截短缺失突变,即657 - 661delACAAA,被确定为NBS患者的致病突变。在本报告中,我们描述了一个马其顿家庭中两名患有NBS和T淋巴细胞母细胞白血病/淋巴瘤的患者。据我们所知,这是马其顿报道的首个NBS家族。两名儿童均表现出小头畸形、并指畸形,分别在7岁和10岁时患上T细胞淋巴细胞母细胞白血病/淋巴瘤。对我们患者的相关基因进行分子分析显示,该基因的657del5突变呈纯合状态。父母为657del5突变的杂合子,他们并不知道有近亲关系。第一个孩子接受了国际柏林 - 法兰克福 - 明斯特(BFM)非霍奇金淋巴瘤(NHL)方案治疗,实现了持续21个月的完全缓解。随后,他出现了伴有白细胞增多的髓系复发,并因致命的中枢神经系统(CNS)并发症死亡。第二个孩子按照2009年儿童和青少年急性淋巴细胞白血病国际协作治疗方案(AIOP - BFM ALL 2009)进行治疗。不幸的是,未实现缓解。